COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection

WY Chi, YD Li, HC Huang, TEH Chan, SY Chow… - Journal of biomedical …, 2022 - Springer
Abstract Coronavirus Disease 2019 (COVID-19) has been the most severe public health
challenge in this century. Two years after its emergence, the rapid development and …

Circular RNA vaccine in disease prevention and treatment

D Niu, Y Wu, J Lian - Signal transduction and targeted therapy, 2023 - nature.com
CircRNAs are a class of single-stranded RNAs with covalently linked head-to-tail topology.
In the decades since its initial discovery, their biogenesis, regulation, and function have …

[HTML][HTML] Immune-mediated disease flares or new-onset disease in 27 subjects following mRNA/DNA SARS-CoV-2 vaccination

A Watad, G De Marco, H Mahajna, A Druyan, M Eltity… - Vaccines, 2021 - mdpi.com
Background: Infectious diseases and vaccines can occasionally cause new-onset or flare of
immune-mediated diseases (IMDs). The adjuvanticity of the available SARS-CoV-2 vaccines …

SARS-CoV-2 vaccines based on the spike glycoprotein and implications of new viral variants

D Martínez-Flores, J Zepeda-Cervantes… - Frontiers in …, 2021 - frontiersin.org
Coronavirus 19 Disease (COVID-19) originating in the province of Wuhan, China in 2019, is
caused by the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), whose …

Potential therapeutic options for COVID-19: an update on current evidence

Z Niknam, A Jafari, A Golchin, F Danesh Pouya… - European journal of …, 2022 - Springer
Abstract SARS-CoV-2, a novel coronavirus, is the agent responsible for the COVID-19
pandemic and is a major public health concern nowadays. The rapid and global spread of …

Adenoviral vector-based vaccine platform for COVID-19: Current status

VP Chavda, R Bezbaruah, D Valu, B Patel, A Kumar… - Vaccines, 2023 - mdpi.com
The coronavirus disease (COVID-19) breakout had an unimaginable worldwide effect in the
21st century, claiming millions of lives and putting a huge burden on the global economy …

COVID-19 vaccine safety and efficacy in patients with immune-mediated inflammatory disease: review of available evidence

S Wack, T Patton, LK Ferris - Journal of the American Academy of …, 2021 - Elsevier
Dermatologists diagnose and treat many immune-mediated inflammatory diseases (IMID).
Understanding the inherent immune dysregulation of these diseases as well as the …

Safety and immunogenicity of an inactivated severe acute respiratory syndrome coronavirus 2 vaccine in a subgroup of healthy adults in Chile

SM Bueno, K Abarca, PA González… - Clinical Infectious …, 2022 - academic.oup.com
Background The development of effective vaccines against coronavirus disease 2019 is a
global priority. CoronaVac is an inactivated severe acute respiratory syndrome coronavirus …

Vaccine development: Current trends and technologies

R Poria, D Kala, R Nagraik, Y Dhir, S Dhir, B Singh… - Life Sciences, 2024 - Elsevier
Despite the effectiveness of vaccination in reducing or eradicating diseases caused by
pathogens, there remain certain diseases and emerging infections for which develo** …

Health equity, care access and quality in headache–part 1

C Tana, B Raffaelli, MNP Souza, ER de la Torre… - The Journal of …, 2024 - Springer
Current definitions of migraine that are based mainly on clinical characteristics do not
account for other patient's features such as those related to an impaired quality of life, due to …